Clinical trials: Breast Neoplasms, Triple-Negative
Triple Negative Breast Cancer
A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
The purpose of this study is to evaluate the efficacy and safety of camrelizumab (an engineered anti-programmed death-ligand 1 [PD-1] antibody) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy in participants…
- Trial name
- NCT04613674
- Testing
- Camrelizumab Plus Chemotherapy
- Where
- China
- Volunteers
- 441 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Triple Negative Breast Cancer, Breast Cancer
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
The purpose of the study is to evaluate the use of a circulating tumor DNA (ctDNA) assay, ie, a "liquid biopsy," as a tool to identify triple-negative breast cancer (TNBC) patients who will or will not experience benefit from…
- Trial name
- NCT04768426
- Testing
- Capecitabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
This phase I trial studies the side effects and best dose of veliparib when given together with carboplatin and to see how well they work in treating patients with human epidermal growth factor 2 (HER2)-negative breast cancer…
- Conditions
- Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT01251874
- Testing
- Biospecimen Collection, Carboplatin, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Breast Diseases
The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer
This study will look at effects the combination of palbociclib and dose-dense neoadjuvant chemotherapy may have on triple negative breast cancer tumours which have not yet been treated.
- Conditions
- Breast Cancer, Breast Diseases, Breast Neoplasms
- Trial name
- PECP (NCT03756090)
- Testing
- Palbociclib, Epirubicin, Cyclophosphamide
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Triple Negative Breast Neoplasms
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)
- Trial name
- CAPItello-290 (NCT03997123)
- Testing
- Capivasertib, Paclitaxel
- Where
- 260 sites in United States, Argentina and 28 more
- Volunteers
- 923 people
- Sponsor
- AstraZeneca
Breast Cancer, Breast Carcinoma
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Background: Breast cancer is the most common cancer among women. It can often spread to the liver, lungs, bones, or brain. Breast cancer that spreads to the brain is often fatal.
- Conditions
- Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast
- Trial name
- NCT07619534
- Testing
- Arm 1
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Ovarian Cancer
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
Background: Carboplatin is approved by the Food and Drug Administration to treat cancer. AZD2281 is an experimental drug in a class of agents called PARP inhibitors.
- Trial name
- NCT01445418
- Testing
- AZ2281 + Carboplatin
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
This phase II trial tests whether panitumumab and pembrolizumab in combination with standard of care chemotherapy before surgery (neoadjuvant) works to shrink tumors in patients with stage III-IV triple negative breast cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT05177796
- Testing
- Carboplatin, Cyclophosphamide, Doxorubicin
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Breast Cancer (Triple Negative Type)
Senocohort: Identification of Predictive Biomarkers in Breast Cancer Treatment
Breast cancer is a heterogeneous disease with multiple molecular subtypes, each requiring tailored therapeutic strategies. The recent introduction of targeted therapies, immunotherapies, and antibody-drug conjugates has expanded…
- Trial name
- SENOCOHORT (NCT07833891)
- Testing
- Patients follow-up
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
NSCLC, SCLC
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research.
- Conditions
- NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT06534762
- Testing
- Mirabegron
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Zhejiang Provincial People's Hospital
Triple Negative Breast Cancer
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
The DIAMOND study is being carried out to evaluate if Datopotamab deruxtecan (Dato-DX) in combination with Durvalumab is more effective than Dato-DXd alone in treating PDL1-negative advanced or metastatic triple negative breast…
- Trial name
- DIAMOND (NCT06954480)
- Testing
- Datopotamab Deruxtecan (Dato-DXd), Durvalumab
- Where
- 2 sites in United Kingdom
- Volunteers
- 140 people
- Sponsor
- Queen Mary University of London
Breast Cancer
An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer
This observational study will evaluate the safety and efficacy of triple negative or HR+ patients with HER2-metastatic or locally advanced breast cancer treated with Avastin (bevacizumab) as first line therapy for at least 12…
- Trial name
- NCT01461044
- Where
- 82 sites in France
- Volunteers
- 228 people
- Sponsor
- Hoffmann-La Roche
Triple Negative Breast Neoplasms
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
The goal of this clinical trial is to evaluate the efficacity and safety of pembrolizumab and capecitabine on the invasive disease-free survival, in participants who have triple negative breast cancer (TNBC) with residual disease…
- Trial name
- CAPPA (NCT05973864)
- Testing
- Pembrolizumab injection, Capecitabine tablets, Local radiotherapy
- Where
- 20 sites in France
- Volunteers
- 220 people
- Sponsor
- UNICANCER
Triple Negative Breast Cancer
Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer
The purpose of this study is to increase survival of patients with early and locally advanced triple-negative breast cancer adding selumatinib to standard preoperative chemotherapy regimen.
- Trial name
- NCT02685657
- Testing
- Drug: Selumetinib, Doxorubicin, Cyclophosphamide
- Volunteers
- 164 people
- Sponsor
- Russian Academy of Medical Sciences
Triple Negative Breast Cancer (TNBC)
Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)
This study aims to collect information about the effects of chemotherapy combined with immunotherapy (immune checkpoint inhibitors) for early-stage triple-negative breast cancer (TNBC) on ovarian function and fertility.
- Trial name
- FERTILE (NCT07527819)
- Where
- 9 sites in Australia
- Volunteers
- 75 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer
This clinical trial evaluates the feasibility and acceptability of a mobile health device in improving oral chemotherapy adherence in women with triple negative breast cancer that has not spread to other places in the body…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT05086731
- Testing
- Best Practice, Informational Intervention, Medical Device Usage and Evaluation
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Emory University
Triple Negative Breast Cancer
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
This is a single-arm Phase II study to assess the efficacy of a 12-18 week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who…
- Trial name
- NeoCARD (NCT06845319)
- Testing
- Carboplatin, Paclitaxel, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Medical University of South Carolina
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Ovarian Neoplasms, Endometrial Neoplasms
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06400472
- Testing
- Sofe-M, bevacizumab, carboplatin
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 575 people
- Sponsor
- Eli Lilly and Company
TNBC - Triple-Negative Breast Cancer
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
To evaluate the efficacy and safety of LM108 plus toripalimab plusnab-paclitaxel or eribulin as first-line or post-line treatment in patients with metastatic triple-negative breast cancer.
- Trial name
- NCT06387628
- Testing
- LM-108, Toripalimab, Eribulin
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.